The fact that aberrant expression of Smad4 is only seen some of ERα-positive infiltrating breast cancer is consistent with the heterogeneity of human breast carcinoma in biological features, development and progression, and therapy response. This evidence concerns the gene ERAL1 and breast carcinoma.